Moruya Medical Centre

EMERGENCY INFORMATION

 

"YOUR PRIVACY IS OUR BUSINESS"

An ethical & confidentiality code, in line with the Australian Medical Association Code of Ethics & the Privacy Act is upheld by all staff at the Moruya Medical Centre
 

 

 

COVID-19 POLICIES

Due to the current increase in 'Omicron' cases and to keep us all as safe as possible during the festive season, the practice policy continues to require all symptomatic patients (fever, cough, sore throat or shortness of breath) to produce a negative COVID swab before being seen in the surgery. We will NOT be accepting at-home rapid tests. The negative swab results must be shown to reception staff

Additionally, whilst restrictions begin to ease, we still require mandatory mask wearing in the waiting/consultation rooms.

COVID-19 VACCINE BOOSTER

Moruya Medical Centre continues to participate in the Australian Governments COVID-19 vaccination roll out and will commence Pfizer booster doses from January 2022. 

Right now you are eligible for a booster if you had your second dose of your primary course of COVID-19 vaccination at least five months ago.

From 4 January 2022, you are eligible for a COVID-19 booster dose if:

• you are 18 years and older, and

• have had your second dose of your primary dose course of COVID-19 vaccination at least  four months ago.

Booster doses are not mandatory, however they are recommended to maintain immunity against COVID-19.

Please ring the surgery to book your appointment.

ATAGI is not currently recommending booster doses for:

• people aged 12 to 17 years

• people who are severely immunocompromised and have already had a third dose.

Read ATAGI’s advice on COVID-19 booster doses.

COVID-19 VACCINES FOR CHILDREN AGED 5 TO 11 YEARS

The Australian Government  will provide COVID-19 vaccines to children aged 5 to 11 years through the COVID-19 Vaccination Program

• This means that anyone in Australia aged 5 to 11 years can receive a COVID-19 vaccine.

• Pfizer is the only vaccine that has been approved for use in this age group.

• The primary course is two doses, with an interval of 8-weeks. The interval can be shorted to a minimum of 3 weeks in special circumstances.

• The roll-out to this age group will commence from 10 January 2022.